Nexalin Technology
7 hedge funds and large institutions have $32.5K invested in Nexalin Technology in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.
500% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 1
250% more funds holding
Funds holding: 2 → 7 (+5)
55% more capital invested
Capital invested by funds: $21K → $32.5K (+$11.5K)
0.34% more ownership
Funds ownership: 0.27% → 0.61% (+0.34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$23.9K |
| 2 |
VF
Virtu Financial
New York
|
+$21.3K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.6K |
| 4 |
Morgan Stanley
New York
|
+$3.13K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$395 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$17K |
NXL Hedge Fund Activity: Q4 2022 in Review
7 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Nexalin Technology (NXL) for Q4 2022, worth a combined $32.5K — up 55% from $21K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new NXL positions and 1 closed out — a net gain of 5 holders — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Susquehanna International Group, opening a new position worth an estimated $23.9K. The largest seller was Citadel Advisors, exiting entirely with an estimated $17K sold.
- 7 institutional investors held Nexalin Technology (NXL) as of Q4 2022, up from 2 in Q3 2022.
- Funds reported $32.5K of Nexalin Technology stock for Q4 2022, up 55% quarter-over-quarter.
- 6 funds opened new Nexalin Technology positions in Q4 2022 and 1 closed out, a net change of +5 holders.
- The largest Nexalin Technology buyer in Q4 2022 was Susquehanna International Group, an estimated $23.9K added.
- The largest Nexalin Technology seller in Q4 2022 was Citadel Advisors, an estimated $17K sold.
Based on aggregated 13F filings for Q4 2022.